Skip to main content
Clinical Trials/NCT01977339
NCT01977339
Withdrawn
Phase 4

A Randomized, Double-Blinded, Control Trial to Evaluate the Efficacy of Single Injection Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia in Subjects Undergoing Unilateral Total Knee Arthroplasty

St. Luke's-Roosevelt Hospital Center1 site in 1 countryMay 2015

Overview

Phase
Phase 4
Intervention
Liposome Bupivacaine
Conditions
Total Knee Arthroplasty
Sponsor
St. Luke's-Roosevelt Hospital Center
Locations
1
Primary Endpoint
Opiate consumption
Status
Withdrawn
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this study is to compare the quality and duration of pain relief after a total knee replacement provided by a single shot of standard bupivacaine versus a single shot of liposomal bupivacaine, at the site of the femoral nerve. It is hypothesized that the liposomal bupivacaine formulation will provide more effective pain relief than standard bupivacaine.

Registry
clinicaltrials.gov
Start Date
May 2015
End Date
July 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female, ≥18 years of age
  • Scheduled to undergo primary unilateral TKA under general anesthesia.
  • American Society of Anesthesiology (ASA) Physical Status I-III
  • Able to demonstrate motor function by performing a 20-meter walk, and sensory function by exhibiting sensitivity to cold.
  • Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.

Exclusion Criteria

  • Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.
  • Planned concurrent surgical procedure (e.g., bilateral TKA).
  • Body weight \< 50 kg (110 pounds) or a body mass index ≥ 40 kg/m
  • Contraindication to any of the pain-control agents planned for postsurgical use (i.e., morphine, hydromorphone, oxycodone, bupivacaine).
  • Previous participation in a liposome bupivacaine study.
  • History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  • Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, could interfere with study assessments or compliance.

Arms & Interventions

Liposome Bupivacaine

Single injection femoral nerve block of 10 cc of 266 mg liposome bupivacaine with 10 cc of normal saline

Intervention: Liposome Bupivacaine

Bupivacaine

Single shot femoral nerve block with 20cc of 0.25% bupivacaine

Intervention: Bupivacaine

Outcomes

Primary Outcomes

Opiate consumption

Time Frame: 72 hours

Compare the cumulative 72 hour opiate consumption after total knee arthroplasty (TKA)in patients who received a single dose of liposome bupivacaine with those who received a single shot femoral nerve block with 0.25% bupivacaine.

Secondary Outcomes

  • Post-operative VAS scores(1 hr, 4 hrs, 8 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs)

Study Sites (1)

Loading locations...

Similar Trials